About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/04/2020.
  • Targeted Antitumor Therapy Using Antibody-Drug Conjugate (ADC) Technology

     The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    ADC molecules are engineered to deliver potent cytotoxic compounds to specific antigen-expressing target cells.1,2 Antigen binding domains recognize specific surface proteins, such as B-cell maturation antigen (BCMA), which allows for targeting of cells expressing BCMA, such as plasma and multiple myeloma cells .1,2 ADCs built with non-natural amino acid linkers could potentially ensure that the cytotoxic payload reaches the target cell.1,3 Cytotoxic molecules induce cell death when internalized by antigen-expressing target cells.3 Preclinical studies have shown that ADCs can attack tumors directly, independent of the immune system.4 Preclinical studies are ongoing to optimize, improve, and assess the potential benefits and risks of ADCs as single agent therapy or in combination with other therapies.3,5

     

    View Related Molecules

    References

    1. Yu B, Liu D. J Hematol Oncol. 2019;12:94. PMID: 31500657
    2. Wolska-Washer A, Robak T. Drug Saf. 2019;42:295-314. PMID: 30649747
    3. Panowski S, et al. MAbs. 2014;6:34-45. PMID: 24423619
    4. Parslow A, et al. Biomedicines. 2016;4(3).pii:E14. PMID: 28536381